<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389985</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX101-209</org_study_id>
    <nct_id>NCT02389985</nct_id>
  </id_info>
  <brief_title>A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewLink Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumos Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when&#xD;
      administered in combination with weekly paclitaxel in women with recurrent or persistent,&#xD;
      epithelial ovarian, fallopian tube or primary peritoneal cancer.&#xD;
&#xD;
      Determine through pharmacokinetic evaluation(sometimes described as what the body does to a&#xD;
      drug, refers to the movement of drug into, through and out of the body-the time and course of&#xD;
      its absorption, bioavailability, distribution, metabolism, and excretion) whether or not the&#xD;
      disposition of paclitaxel is affected by the concurrent administration of CRLX101.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent ovarian cancer represents a therapeutic challenge. Patients with resistant disease,&#xD;
      showing progression within six months of platinum-containing therapy, have a poor prognosis,&#xD;
      with median overall survival (OS) approximately 12 months.Ultimately most patients with&#xD;
      recurrent disease ultimately develop platinum resistance, and novel strategies are needed.&#xD;
&#xD;
      In this setting the most active agents are pegylated liposomal doxorubicin (PLD), paclitaxel&#xD;
      and topotecan. Multiple trials have demonstrated that combination therapy produces increased&#xD;
      toxicity without improved efficacy.&#xD;
&#xD;
      This study proposes to examine the combination of CRLX101 in combination with weekly&#xD;
      paclitaxel. Preclinical studies show synergistic activity in the SKOV3 human ovarian cancer&#xD;
      xenograft ovarian cancer cell lines (14), as well as in vivo (15,16), perhaps via an&#xD;
      antiangiogenic mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 18, 2018</completion_date>
  <primary_completion_date type="Actual">June 4, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. To estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>The highest dose with &lt;2 patients with DLTs out of 6 DLT-evaluable patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of pharmacokinetic perimeters including max concentration (Cmax), time to maximum concentration (Tmax), AUC, elimination half-life for CRLX101 and paclitaxel</measure>
    <time_frame>6 months</time_frame>
    <description>PK</description>
  </secondary_outcome>
  <other_outcome>
    <measure>2. To assess the overall safety and tolerability of CRLX101 in combination with weekly paclitaxel.</measure>
    <time_frame>6 months</time_frame>
    <description>AEs, changes in clinical status, vital signs, and laboratory data</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the anti-tumor activity of CRLX101 when administered concomitantly with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian fallopian tube or primary peritoneal cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>PFS per RECIST 1.1 with scans every 2 cycles</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>CRLX101 and weekly paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRLX101</intervention_name>
    <arm_group_label>CRLX101 and weekly paclitaxel</arm_group_label>
    <other_name>NLG207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>CRLX101 and weekly paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or&#xD;
             primary peritoneal carcinoma. Histologic documentation of the original primary tumor&#xD;
             is required via the pathology report.&#xD;
&#xD;
          2. Patient must have measurable disease or detectable (non-measurable) disease:&#xD;
&#xD;
             Measurable disease will be defined by RECIST 1.1.&#xD;
&#xD;
          3. Patients must have adequate bone marrow, renal, hepatic, and neurologic functions&#xD;
&#xD;
          4. Patients should be free of active infection requiring parenteral antibiotics.&#xD;
&#xD;
          5. Any other prior therapy directed at the malignant tumor, including chemotherapy,&#xD;
             bevacizumab or other biologic or targeted agents and immunologic agents, must be&#xD;
             discontinued at least 21 days (three weeks) prior to registration.&#xD;
&#xD;
          6. Any prior radiation therapy must be discontinued at least four weeks prior to&#xD;
             registration.&#xD;
&#xD;
          7. Major surgery within 28 days (four weeks) prior to registration.&#xD;
&#xD;
          8. Patients must have had one prior platinum-based chemotherapeutic regimen for&#xD;
             management of primary disease.&#xD;
&#xD;
          9. Patients must have a GOG performance status of 0 or 1.&#xD;
&#xD;
         10. Patients who will be enrolled under protocol amendment # 2 must have previously&#xD;
             received bevacizumab, either discontinued due to intolerability, or progressed after&#xD;
             at least 2 cycles of bevacizumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have had previous treatment with:&#xD;
&#xD;
               -  CRLX101 or with any topoisomerase I therapy;&#xD;
&#xD;
               -  Weekly paclitaxel for recurrent or persistent disease.&#xD;
&#xD;
          2. Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin, are excluded if:&#xD;
&#xD;
               -  There is any evidence of other malignancy being present within the last three&#xD;
                  years;&#xD;
&#xD;
               -  Previous cancer treatment contraindicates this protocol therapy.&#xD;
&#xD;
          3. Patients with known active hepatitis or HIV.&#xD;
&#xD;
          4. Patients with history or evidence upon physical examination of CNS disease, including&#xD;
             primary brain tumor, seizures not controlled with standard medical therapy, any brain&#xD;
             metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic&#xD;
             attack (TIA) or subarachnoid hemorrhage within six months of the first dose of study&#xD;
             drug.&#xD;
&#xD;
          5. Patients with clinically significant cardiovascular disease.&#xD;
&#xD;
          6. Patients with serous non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          7. Patients with active bleeding or pathologic conditions that carry high risk of&#xD;
             bleeding&#xD;
&#xD;
          8. Patients with clinical symptoms or signs of gastrointestinal obstruction and who&#xD;
             require parenteral hydration and/or nutrition.&#xD;
&#xD;
          9. Patients with active infection requiring parenteral antibiotics.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma / Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <disposition_first_submitted>February 21, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 21, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 25, 2019</disposition_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

